Allylamine antifungal
Terbinafine
Brand names: Lamisil
Adult dose
Dose: Onychomycosis: 250mg PO OD x6 weeks (fingernails) or 12 weeks (toenails). Tinea: 250mg OD x2-6 weeks
Route: PO/Topical
Frequency: OD
Dose adjustments
Renal
Reduce if eGFR <50
Clinical pearls
- Dermatophyte onychomycosis (1st-line)
- Confirm with mycology; check LFTs baseline + 4–6 weeks
Contraindications
- Severe hepatic impairment
- Active liver disease
- Hypersensitivity
Side effects
- Hepatotoxicity (boxed)
- Taste disturbance
- Cytopenias
- Severe skin reactions (SJS/TEN, DRESS)
- SLE-like syndrome
Interactions
- CYP2D6 substrates
- Warfarin
- Caffeine
Monitoring
- LFTs
- FBC
Reference: BNF; NICE CKS; MHRA; https://bnf.nice.org.uk/drugs/terbinafine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023